Agendia Hoping Fourth FDA Clearance for MammaPrint Convinces Payors

The additional clearance for MammaPrint, which will allow the company to market the test to women older than 61 years, gives the company "another powerful argument in favor of [the test,] in addition to the abundance of validating studies, previous FDA clearances," and other factors, a company spokesperson said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.